Shares of Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial. Specifically, the firm reported positive top-line results from a global, pivotal Phase 3 clinical study comparing its once-daily oral and intravenous, broad spectrum investigational antibiotic, omadacycline, to moxifloxacin in the treatment of patients with community-acquired bacterial pneumonia.
